Tag: Pharnext
PHARNEXT: Fundraising of 250 thousand euros – 01/31/2024 at 7:00 p.m.
PARIS, France, January 31, 2024 at 7 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Pharnext: launches a drastic cost reduction plan
(CercleFinance.com) – Pharnext announces the implementation of a drastic cost reduction plan as the company continues its work to develop PXT3003, its drug candidate for Charcot-Marie-Tooth disease type 1A (CMT1A).…
PHARNEXT: Information relating to the total number of voting rights and shares making up the share capital and the par value of the shares – 01/02/2024 at 6:00 p.m.
PARIS, France, January 2, 2024 at 6 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative…
Pharnext: Consolidation of actions
(Boursier.com) — Pharnext SCA, a biopharmaceutical company at an advanced clinical stage developing new therapies for neurodegenerative diseases without a satisfactory therapeutic solution, announces that it has decided to implement…
PHARNEXT: Pharnext announces its intention to prepare registration and marketing authorization files for PXT3003, its drug candidate in Charcot-Marie-Tooth disease type 1A – 12/19/2023 at 08:00: 00
PARIS, France, December 19, 2023 at 8:30 a.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…
Pharnext divides the nominal value of its shares by ten
(AOF) – Pharnext announces today that the management of the company, on the basis of the 7th resolution voted at the General Meeting of June 30, 2023, has decided to…
Pharnext raises 1.5 million euros through Oceane-BSA issue – 05/12/2023 at 6:17 p.m.
(AOF) – Pharnext announces a fundraising of 1.5 million euros through the issue of Oceane-BSA subscribed by Global Tech Opportunities 13. This biopharmaceutical company at an advanced clinical stage developing…
Pharnext raises 1.5 million euros through Oceane-BSA issue
(AOF) – Pharnext announces a fundraising of 1.5 million euros through the issue of Oceane-BSA subscribed by Global Tech Opportunities 13. This biopharmaceutical company at an advanced clinical stage developing…
Pharnext: data from the phase III study are frozen – 04/12/2023 at 12:31
(CercleFinance.com) – Pharnext announced on Monday the freezing of data from its pivotal phase III study in Charcot Marie-Tooth disease type 1A, the last step before the publication of the…
Pharnext: data from the phase III study are frozen
(CercleFinance.com) – Pharnext announced on Monday the freezing of data from its pivotal phase III study in Charcot Marie-Tooth disease type 1A, the last step before the publication of the…
PHARNEXT: Information relating to the total number of voting rights and shares making up the share capital and the par value of the shares – 01/12/2023 at 6:00 p.m.
PARIS, France, 1 er December 2023 at 6 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), a biopharmaceutical company at an advanced clinical stage developing new therapies for…
PHARNEXT: Fundraising of 0.5 million euros – 11/24/2023 at 8:00 p.m.
PARIS, France, November 24, 2023 at 8 p.m. (CET) – Pharnext SCA (FR001400JXB0 – ALPHA) (the “Company”), an advanced clinical stage biopharmaceutical company developing new therapies for neurodegenerative diseases without…